A focus on symptom control over exacerbation risk in asthma may hinder uptake of GINA guidance featuring ICS/formoterol as the preferred asthma reliever treatment, even in mild asthma, and as maintenance and reliever therapy (MART). About 1,200 adults from Australia, Canada, China, and the Philippines responded to a 2020 online survey in the Asthma Patients’ ...
Asthma behaviour yet to catch up with GINA guidance
By Mardi Chapman
5 Jul 2021